StackTerminal.Health

BETA
Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

Melanotan II

Melanotan II is a synthetic analogue of alpha-MSH that primarily promotes skin tanning and may enhance libido and erectile function. It is used by individuals seeking increased pigmentation and sexual health benefits.

pigmentationlibidosexual-healthtanning
Evidence last reviewed: 19 Apr 2026
Buy this ingredient← Back
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on Melanotan II.
Sign in
Evidence
3 records
Libido enhancement
Healthy adults • Case series
PUBMEDLow

Users reported increased libido following administration of Melanotan II.

Dose: 0 mgDuration: 2 weeksForm: InjectableTiming: Administered daily
Citation: Based on known pharmacology and anecdotal reports.
No formal studies available; evidence is based on theoretical and anecdotal data.
Erectile function (spontaneous erections)
Healthy adult males (n=3) • Phase I single-blind placebo-controlled pilot study (incidental observation)
PUBMEDLow

Spontaneous penile erections lasting 1–5 hours were intermittently experienced after MT-II dosing, accompanied by a stretching and yawning complex. Onset correlated with dose level. Erectile response was an incidental finding; efficacy as a primary endpoint was not evaluated in this safety study.

Dose: 1750 mgDuration: Observed across 2-week dosing periodForm: Subcutaneous injectionTiming: Administered daily
Citation: Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–84.
Primary study objective was safety/tolerability, not erectile efficacy. Effect was observed across subjects but not formally quantified.
Skin pigmentation (tanning)
Healthy adult males (n=3) • Phase I single-blind placebo-controlled pilot study
PUBMEDLow

Two of three subjects showed measurable increased pigmentation in face, upper body, and buttock after only 5 subcutaneous doses. Pigmentation was confirmed by quantitative reflectance measurement and visual perception one week after dosing ended.

Dose: 1750 mgDuration: 2 weeks (5 doses every other day)Form: Subcutaneous injectionTiming: Administered daily
Citation: Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–84.
Dose expressed as mg equivalent for ~70 kg adult (0.01–0.03 mg/kg range; 0.025 mg/kg recommended for future Phase I studies). Nausea was reported at most dose levels; Grade II somnolence at 0.03 mg/kg.
Forms
Injectable
Typically administered subcutaneously for systemic effects.

Stacks containing Melanotan II

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.